MX379245B - Compuesto de tres ciclos y aplicaciones del mismo - Google Patents
Compuesto de tres ciclos y aplicaciones del mismoInfo
- Publication number
- MX379245B MX379245B MX2019010042A MX2019010042A MX379245B MX 379245 B MX379245 B MX 379245B MX 2019010042 A MX2019010042 A MX 2019010042A MX 2019010042 A MX2019010042 A MX 2019010042A MX 379245 B MX379245 B MX 379245B
- Authority
- MX
- Mexico
- Prior art keywords
- applications
- cycles
- same
- tautomer
- drugs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen en la presente invención un compuesto representado por la Fórmula (I), un tautómero del mismo o una sal farmacéuticamente aceptable del mismo, y aplicaciones de los mismos en la preparación de fármacos para tratar enfermedades relacionadas con VHB. (ver fórmula I).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710100309 | 2017-02-23 | ||
| CN201710648155 | 2017-08-01 | ||
| CN201810008592 | 2018-01-04 | ||
| PCT/CN2018/075995 WO2018153285A1 (zh) | 2017-02-23 | 2018-02-09 | 三并环类化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019010042A MX2019010042A (es) | 2020-01-13 |
| MX379245B true MX379245B (es) | 2025-03-10 |
Family
ID=63253508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010042A MX379245B (es) | 2017-02-23 | 2018-02-09 | Compuesto de tres ciclos y aplicaciones del mismo |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11053260B2 (es) |
| EP (1) | EP3587420B1 (es) |
| JP (1) | JP6764039B2 (es) |
| KR (1) | KR102085497B1 (es) |
| CN (1) | CN109071544B (es) |
| AU (1) | AU2018223435B2 (es) |
| CA (1) | CA3054324C (es) |
| DK (1) | DK3587420T3 (es) |
| ES (1) | ES2874656T3 (es) |
| HU (1) | HUE054822T2 (es) |
| IL (1) | IL268827A (es) |
| LT (1) | LT3587420T (es) |
| MX (1) | MX379245B (es) |
| MY (1) | MY175445A (es) |
| PH (1) | PH12019501955A1 (es) |
| PL (1) | PL3587420T3 (es) |
| PT (1) | PT3587420T (es) |
| RS (1) | RS61913B1 (es) |
| SG (1) | SG11201907725SA (es) |
| SI (1) | SI3587420T1 (es) |
| WO (1) | WO2018153285A1 (es) |
| ZA (1) | ZA201906135B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12318393B2 (en) | 2018-05-03 | 2025-06-03 | Emory University | Modulators of orphan nuclear receptors for NASH and other metabolic disorders |
| TWI742419B (zh) * | 2018-08-23 | 2021-10-11 | 大陸商福建廣生堂藥業股份有限公司 | 三并環類化合物的晶型及其應用 |
| CN110172068A (zh) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用 |
| JP7433415B2 (ja) * | 2019-08-15 | 2024-02-19 | 福建▲広▼生中霖生物科技有限公司 | オキサゼピン系化合物の調製方法 |
| CN115702152B (zh) * | 2020-04-22 | 2025-10-10 | 南京明德新药研发有限公司 | 内磺酰胺衍生物及其应用 |
| US12569500B2 (en) | 2020-05-15 | 2026-03-10 | Fujian Akeylink Biotechnology Co., Ltd. | Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV |
| CN114456099A (zh) * | 2022-02-21 | 2022-05-10 | 八叶草健康产业研究院(厦门)有限公司 | 一种4-氯吡咯-2-羧酸的制备方法 |
| WO2026052081A1 (zh) * | 2024-09-06 | 2026-03-12 | 福建广生中霖生物科技有限公司 | 用于治疗乙型肝炎的药物及组合 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE45004E1 (en) | 2007-06-18 | 2014-07-08 | Sunshine Lake Pharma Co., Ltd. | Bromo-phenyl substituted thiazolyl dihydropyrimidines |
| CN102060786A (zh) * | 2011-01-20 | 2011-05-18 | 天津大学 | 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用 |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| EA201690979A1 (ru) | 2013-11-14 | 2016-08-31 | Новира Терапьютикс, Инк. | Производные азепана и способы лечения инфекций гепатита в |
| MX363600B (es) | 2014-03-13 | 2019-03-28 | Univ Indiana Res & Tech Corp | Moduladores alostericos de proteina nucleo de hepatitis b. |
| EP3143020B1 (en) * | 2014-05-13 | 2019-08-21 | F. Hoffmann-La Roche AG | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection |
| TWI721016B (zh) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| CN108431004B (zh) | 2015-10-23 | 2021-02-12 | 武田药品工业株式会社 | 杂环化合物 |
| US10987360B2 (en) * | 2016-09-15 | 2021-04-27 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
-
2018
- 2018-02-09 PL PL18757445T patent/PL3587420T3/pl unknown
- 2018-02-09 ES ES18757445T patent/ES2874656T3/es active Active
- 2018-02-09 HU HUE18757445A patent/HUE054822T2/hu unknown
- 2018-02-09 DK DK18757445.4T patent/DK3587420T3/da active
- 2018-02-09 CN CN201880001646.8A patent/CN109071544B/zh active Active
- 2018-02-09 US US16/488,244 patent/US11053260B2/en active Active
- 2018-02-09 CA CA3054324A patent/CA3054324C/en active Active
- 2018-02-09 LT LTEP18757445.4T patent/LT3587420T/lt unknown
- 2018-02-09 SG SG11201907725SA patent/SG11201907725SA/en unknown
- 2018-02-09 MX MX2019010042A patent/MX379245B/es unknown
- 2018-02-09 JP JP2019557752A patent/JP6764039B2/ja active Active
- 2018-02-09 RS RS20210671A patent/RS61913B1/sr unknown
- 2018-02-09 WO PCT/CN2018/075995 patent/WO2018153285A1/zh not_active Ceased
- 2018-02-09 PT PT187574454T patent/PT3587420T/pt unknown
- 2018-02-09 SI SI201830287T patent/SI3587420T1/sl unknown
- 2018-02-09 AU AU2018223435A patent/AU2018223435B2/en active Active
- 2018-02-09 EP EP18757445.4A patent/EP3587420B1/en active Active
- 2018-02-09 MY MYPI2019004841A patent/MY175445A/en unknown
- 2018-02-09 KR KR1020197027723A patent/KR102085497B1/ko active Active
-
2019
- 2019-08-21 IL IL26882719A patent/IL268827A/en active IP Right Grant
- 2019-08-23 PH PH12019501955A patent/PH12019501955A1/en unknown
- 2019-09-17 ZA ZA2019/06135A patent/ZA201906135B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019017603A2 (pt) | 2020-03-24 |
| US20200247819A1 (en) | 2020-08-06 |
| IL268827A (en) | 2019-11-03 |
| US11053260B2 (en) | 2021-07-06 |
| CA3054324A1 (en) | 2018-08-30 |
| MX2019010042A (es) | 2020-01-13 |
| CN109071544A (zh) | 2018-12-21 |
| PH12019501955A1 (en) | 2020-07-06 |
| WO2018153285A1 (zh) | 2018-08-30 |
| CN109071544B (zh) | 2020-03-17 |
| KR102085497B1 (ko) | 2020-03-05 |
| LT3587420T (lt) | 2021-07-12 |
| RS61913B1 (sr) | 2021-06-30 |
| SG11201907725SA (en) | 2019-09-27 |
| AU2018223435A1 (en) | 2019-10-10 |
| JP6764039B2 (ja) | 2020-09-30 |
| CA3054324C (en) | 2020-12-01 |
| PT3587420T (pt) | 2021-06-04 |
| EP3587420A4 (en) | 2020-02-19 |
| KR20190120300A (ko) | 2019-10-23 |
| ES2874656T3 (es) | 2021-11-05 |
| EP3587420B1 (en) | 2021-03-31 |
| AU2018223435B2 (en) | 2020-12-24 |
| DK3587420T3 (da) | 2021-06-07 |
| JP2020508342A (ja) | 2020-03-19 |
| HUE054822T2 (hu) | 2021-10-28 |
| EP3587420A1 (en) | 2020-01-01 |
| PL3587420T3 (pl) | 2021-10-11 |
| ZA201906135B (en) | 2021-04-28 |
| SI3587420T1 (sl) | 2021-09-30 |
| MY175445A (en) | 2020-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX379245B (es) | Compuesto de tres ciclos y aplicaciones del mismo | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
| HUE045137T2 (hu) | HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| MX388591B (es) | Derivados de pirazolopirimidina como inhibidor de cinasa. | |
| EA201891644A1 (ru) | Антибактериальные соединения и их применение | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201990833A1 (ru) | Соединение пиридина | |
| MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| UA118149C2 (uk) | Інгібітор jak | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| LT3805220T (lt) | Policikliniai karbamoilpiridono dariniai, skirti živ gydymui | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| LT3436074T (lt) | Tiazolido junginiai, skirti virusinių infekcijų gydymui | |
| MX383931B (es) | Compuestos de aza-piridona y usos de estos. | |
| MX2016014939A (es) | Derivados de carboxamida. | |
| CY1124527T1 (el) | Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση | |
| MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
| EA201692298A1 (ru) | Производные карбоксамидов |